MAINZ BIOMED NV (MYNZ) Stock Analyst Ratings
USA - NASDAQ:MYNZ - NL0015000LC2 - Common Stock
1.57 USD
-0.03 (-1.88%)
1.6 USD
+0.03 (+1.91%)
ChartMill assigns a Buy % Consensus number of 83% to MYNZ. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 14.28. This target is 809.55% above the current price.
MYNZ was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about MYNZ.
In the previous month the buy percentage consensus was at a similar level.
MYNZ was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-02-14 | Maxim Group | Initiate | Buy |
| 2024-11-25 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-04-12 | Cantor Fitzgerald | Reiterate | Neutral |
| 2024-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-21 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2023-11-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-26 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-09-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-01 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-18 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-04-27 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-30 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-16 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-10 | JonesTrading | Initiate | Buy |
| 2022-10-25 | Cantor Fitzgerald | Initiate | Overweight |
| 2022-06-21 | HC Wainwright & Co. | Initiate | Buy |
MAINZ BIOMED NV / MYNZ FAQ
Can you provide the average price target for MAINZ BIOMED NV stock?
7 analysts have analysed MYNZ and the average price target is 14.28 USD. This implies a price increase of 809.55% is expected in the next year compared to the current price of 1.57.
How do analysts rate MAINZ BIOMED NV (MYNZ)?
The consensus rating for MAINZ BIOMED NV (MYNZ) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for MAINZ BIOMED NV stock?
The number of analysts covering MAINZ BIOMED NV (MYNZ) is 7.